Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mycophenolate→

Mycophenolate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
24280-93-1
Molecular formula
C17H19O6-
Molecular weight
319.3 g/mol
Drug class
Immunosuppressant antimetabolitemycophenolic acid active moiety
Mechanism of action
Inhibits inosine monophosphate dehydrogenase (IMPDH), preferentially suppressing de-novo guanosine nucleotide synthesis in activated T and B lymphocytes and reducing lymphocyte proliferation. Specific prodrug salts/forms such as mycophenolate mofetil and mycophenolate sodium are separate dosage forms that deliver mycophenolic acid.
Indications / reported uses
  • Used in combination immunosuppressive regimens to prevent allograft rejection after kidney, heart or liver transplantation, depending on the particular mycophenolic acid formulation and jurisdiction
  • Off-label use in selected autoimmune disorders is not a universal product-authorised indication

Sources: US DailyMed — Mycophenolate mofetil labels · NLM MeSH — Mycophenolic acid · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Immunosuppressant antimetabolite; mycophenolic acid active moiety

Mechanism of action

Inhibits inosine monophosphate dehydrogenase (IMPDH), preferentially suppressing de-novo guanosine nucleotide synthesis in activated T and B lymphocytes and reducing lymphocyte proliferation. Specific prodrug salts/forms such as mycophenolate mofetil and mycophenolate sodium are separate dosage forms that deliver mycophenolic acid.

General use cases

  • Used in combination immunosuppressive regimens to prevent allograft rejection after kidney, heart or liver transplantation, depending on the particular mycophenolic acid formulation and jurisdiction
  • Off-label use in selected autoimmune disorders is not a universal product-authorised indication

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Mycophenolate Environmental Risk Assessment (ERA) (the Mycophenolate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.